33 results about "Tumor Load" patented technology

The present disclosure provides methods and systems for screening or detecting a colorectal cancer or following colorectal disease progression that may be applied to cell-free nucleic acids such as cell-free DNA. The method may use detection of methylation signals within a single sequencing read in identified genomic regions as input features to train a machine learning model and generate a classifier useful for stratifying populations of individuals. The method may comprise extracting DNA from a cell-free sample obtained from a subject, converting the DNA for methylation sequencing, generating sequencing reads, and detecting colon proliferative cell disorder-associated signals in the sequencing information and training a machine learning model to provide a discriminator capable of distinguishing groups in a subject population such as healthy, cancer or distinguishing disease subtype or stage. The method may be used for, e.g., predicting, prognosticating, and / or monitoring response to treatment, tumor load, relapse, or colorectal cancer development.

The invention discloses application of sorafenib in maintenance treatment of acute myelogenous leukemia after transplantation, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: it is found for the first time that secretion and killing functions of NK cells can be enhanced by using sorafenib for maintenance treatment after transplantation; sorafenib enhances communication between macrophages and NK cells by promoting secretion of macrophage proinflammatory factors, so that the function of NK cells is enhanced. The invention clarifies that sorafenib enhances the GVL effect of NK cells in a low tumor load environment, discusses the molecular mechanism of sorafenib for enhancing the NK cell function by promoting macrophage metabolism reprogramming, and provides a new thought for maintaining precision and optimization of treatment after transplantation.

The present application relates to the field of intelligent medical treatment, in particular to a tumor treatment dosing regimen Pareto optimization method based on forward-backward stochastic differential equation. The present application unifies the terminal tumor load, dosing cost and treatment risk into the same stochastic control framework, can establish the Pareto optimality condition corresponding to the nonlinear model, and further converts into the implementable closed-loop state feedback control law in the LQ case. Through the combination with the numerical example and the Pareto frontier analysis, an implementable, interpretable and scalable technical path is provided for the multi-objective individualized treatment regimen design, which can solve the problem that the existing technology is difficult to uniformly process the terminal therapeutic effect, dosing consumption and cumulative risk, and difficult to obtain the implementable closed-loop feedback strategy under the forward-backward stochastic control framework.

The application discloses biomarkers for early diagnosis of lung adenocarcinoma and / or classification of unknown lung nodules and application thereof, and relates to the technical field of biological medicine.The biomarkers are piR-hsa-8429916 or piR-hsa-8393202.Two core biomarkers, piR-hsa-8393202 and piR-hsa-8429916, are successfully identified by screening and verifying piRNAs differentially expressed in lung adenocarcinoma tissues and serum, and the expression levels of the biomarkers are significantly positively correlated with tumor load.The diagnostic value of piR-hsa-8393202 and piR-hsa-8429916 in early diagnosis of lung adenocarcinoma and classification of lung nodules is significantly better than that of a traditional CEA marker.The application provides an innovative solution for early diagnosis of lung adenocarcinoma and risk stratification of lung nodules.

The present application relates to the field of liver cancer immunotherapy efficacy evaluation method combining imageomics and deep learning, and specifically discloses a liver cancer immunotherapy efficacy evaluation method combining imageomics and deep learning. The method comprises the following steps: acquiring multi-modal medical images and clinical information of a liver cancer patient; performing standardization preprocessing and automatic lesion segmentation on the images; extracting features through a multi-scale deep network and realizing semantic alignment by using a cross-modal attention mechanism; fusing the images and the clinical data to construct a multi-source heterogeneous feature matrix; adopting a hierarchical model structure, modeling the spatial distribution of tumor immune microenvironment by using a graph neural network at the bottom layer, dynamically tracking the evolution of efficacy by using a gated recurrent unit at the upper layer, and finally outputting an immune response probability, a tumor load trend and a treatment response grade. The present application can objectively and quantitatively evaluate the efficacy of liver cancer immunotherapy, and improve the precision and automation level of individualized diagnosis and treatment decision-making.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The present disclosure provides a probe set for judging the systemic tumor burden of triple-negative breast cancer and application thereof, the probe set provided by the present disclosure can be used for detecting the gene markers of triple-negative breast cancer and for evaluating the systemic tumor burden, and can achieve good coverage and capture of the target region, obtain sufficient read information on the target region, and overcome the spatial and temporal heterogeneity of tumors to a certain extent, while improving the capture efficiency, stabilizing the experimental system, and meeting the requirements of clinical detection.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The invention discloses a probe set for evaluating pancreatic cancer whole-body tumor load and application thereof.The probe set comprises probes used for detecting gene markers, the gene markers comprise KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, high-frequency and medication-related sites of pancreatic cancer are covered, targeted capture is conducted on plasma ctDNA independently or when the probe set and a personalized probe set are used in an overlapped mode, and the pancreatic cancer whole-body tumor load is evaluated. And the whole-body tumor load of the pancreatic cancer patient is dynamically monitored in real time.

The present application relates to the biomedical technology field, and is an inhibitor targeting CCDC137 gene and application thereof in preparation of a drug for diagnosing and treating acute myeloid leukemia, wherein the inhibitor targeting CCDC137 gene is shRNA. The present application discloses, for the first time, that CCDC137 gene is a new therapeutic target and a prognostic biomarker for acute myeloid leukemia. Experiments prove that inhibition of CCDC137 gene can significantly reduce AML cell proliferation, prolong the survival of an animal model, and reduce tumor load. Based on this finding, the present application provides a therapeutic strategy for treating AML by inhibiting the expression of CCDC137 gene, provides a new therapeutic strategy for AML patients, and reduces the recurrence cost through targeted therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted beta-catenin palmitoylation small-molecule inhibitor and application thereof in treatment of colorectal cancer. The application of beta-cat-Oxazole in preparation of the medicine for treating the colorectal cancer is provided for the first time, the beta-cat-Oxazole can specifically target an interaction interface (residues near C466) of ZDHHC5 and beta-catenin, and other functions or normal physiological signal channels of the beta-catenin are not affected. Due to the accuracy, the miss-target risk is remarkably reduced, and a treatment window is wider. The compound can be used as a single drug in a preclinical model to significantly inhibit tumor growth; in an AOM / DSS induced colorectal cancer model, the tumor load is reduced by about 50%. In addition, the invention discloses a core mechanism of a targeted ZDHHC5-beta-catenin interaction interface, and a new structural basis is provided for subsequent drug target design.

Embodiments of the present disclosure pertain to methods of assessing glioma in a subject by (1) receiving a plurality of measured biomarker levels of the subject; and (2) assessing glioma in the subject based on the measured biomarker levels by at least correlating differentially expressed levels of the measured biomarkers to at least one of (a) diagnosis of glioma, (b) progression of glioma, (c) treatment outcome, and / or (d) tumor burden. The methods of the present disclosure also include a step of (3) making a treatment decision based on the assessment. Additional embodiments of the present disclosure pertain to systems for assessing glioma in a subject.

The present disclosure provides methods and systems for detecting colorectal cancer by nucleic acid methylation analysis. In particular, the present disclosure provides methods and systems for screening or detecting colorectal cancer or subsequent colorectal disease progression, which can be applied to cell-free nucleic acids, such as cell-free DNA. The method may train a machine learning model using detection of methylation signals within a single sequencing read in an identified genomic region as an input feature and generate a classifier suitable for layering a population of individuals. The method may include extracting DNA from a cell-free sample obtained from a subject, transforming the DNA for methylation sequencing, generating a sequencing read, and detecting a colonic proliferative cell disorder related signal in sequencing information, and training a machine learning model to provide a discriminator, the discriminator is capable of differentiating groups, such as health, cancer, or differentiating disease subtypes or stages, in a population of subjects. The methods are useful, for example, in predicting, prognosing, and / or monitoring response to treatment, tumor load, recurrence, or progression of colorectal cancer.

The application discloses an siRNA targeting ACADL, a lipid nanoparticle containing the same and application thereof. The application also relates to a pharmaceutical composition containing the lipid nanoparticle and use of an agent for inhibiting ACADL in preparation of a drug for treating peritoneal metastasis of colorectal cancer. The siRNA and the lipid nanoparticle containing the same can effectively inhibit cancer cell proliferation and invasion, reduce tumor load of peritoneal metastasis foci and have the advantages of selectively knocking down tumor ACADL expression and reducing systemic toxicity by targeting inhibition of a fatty acid oxidation (FAO) process of tumor cells.

The application discloses a biomarker for prognosis evaluation of extrahepatic cholangiocarcinoma, a prognosis risk evaluation system and application, and belongs to the technical field of bioinformatics. The application adopts the combination of miR-34c-5p, miR-100-5p, miR-193b-5p, miR-122-5p, miR-5588-5p and miR-122-3p as a biomarker, can effectively improve the accuracy of differential diagnosis of extrahepatic cholangiocarcinoma, can distinguish extrahepatic cholangiocarcinoma patients from healthy people and benign biliary disease patients with high precision, and overcomes the limitation that traditional tumor markers such as CA19-9 are prone to false positive results in benign biliary diseases. Meanwhile, the expression level change of the biomarker combination can dynamically reflect the postoperative tumor load change, and is helpful for accurately evaluating the surgical effect.

The invention discloses an in-vivo evaluation method for the curative effect of NK cells on human ovarian cancer ascites tumor, which comprises the following steps: inoculating human ovarian cancer cells into the abdominal cavity of a female healthy mouse, and establishing a nude mouse model of the human ovarian cancer ascites tumor; nude mouse models are grouped, and intraperitoneal injection administration is carried out on each group of mice; and carrying out fluorescence tracing on the dosed mouse by adopting a fluorescence imaging method, observing the health and death conditions of the mouse at the same time, and judging the treatment effect of the NK cells on the human ovarian cancer ascites tumor. An ovarian cancer mouse model is established through intraperitoneal injection of an SK-OV-3 cell strain, the treatment effect of NK cells on human ovarian cancer ascites tumor in an in-vivo peritoneal complex environment is evaluated, the result is closer to the actual situation, and the detection result is accurate. The compound is applied to preparation of medicines for treating human ovarian cancer ascites tumor, and can significantly prolong the lifetime, reduce the death rate, reduce the tumor load and improve the life quality.

The invention disclosed herein generally relates to methods of assessing and monitoring tumor load through analysis of tumor DNA in cancer patients. Quantitative measures derived from cell-free DNA and germline DNA are used to assess and monitor tumor load. By assessing and monitoring tumor load, cancer may be detected in a subject. The tumor load of a subject may be assessed at a number of different time points to monitor a progression, regression, or recurrence of cancer in a subject.

The application relates to the technical field of medical data processing, and discloses an osteosarcoma prognosis risk prediction system. The osteosarcoma prognosis risk prediction system is constructed by integrating non-invasive and easily-obtained multi-dimensional clinical data (including demographic and baseline clinical data, tumor load and malignancy data, and serum tumor marker data) and training an optimized machine learning model (such as a random forest). The osteosarcoma prognosis risk prediction model and system can realize early warning, real-time monitoring and accurate grading, can realize early, real-time and non-invasive evaluation and grading early warning of the prognosis risk of patients, solve the problems that existing monitoring means are lagging, invasive and cannot be frequently performed, provide objective and quantitative basis for clinical identification of high-risk patients and development of individualized strategies, and provide strong technical support for improvement of the management and prognosis of osteosarcoma patients.

The application relates to application of BAHD1 as a target point in preparation of a leukemia treatment drug and belongs to the technical field of biological medicine. In order to solve the problems of high drug resistance and high recurrence of an acute leukemia treatment scheme, the application provides application of BAHD1 as a target point in preparation of a leukemia treatment drug. It is proved that BAHD1 is highly expressed in acute leukemia cells, and is used as a molecular marker for diagnosis of acute leukemia. It is proved that knocking out BAHD1 can significantly inhibit proliferation and self-renewal of the acute leukemia cells, promote apoptosis and differentiation of the acute leukemia cells, effectively inhibit proliferation of leukemia cells in the body, reduce tumor load and extramedullary infiltration, and significantly prolong the survival period. In addition, knocking out BAHD1 can significantly enhance the sensitivity of the acute leukemia cells to traditional chemotherapy drugs and targeted treatment drugs.

The invention relates to the technical field of biological medicines, in particular to an application of Alzvudine in tumor prevention. Studies show that the alzovudine can inhibit tumor immune escape, reduce the number of tumors, reduce tumor load and inhibit tumor growth, so that the alzovudine has a good prevention effect on intestinal cancer and melanoma. The alzovudine is good in curative effect, low in toxic and side effects and suitable for long-term administration of patients.

This invention relates to the preparation and application of an oncolytic virus that specifically promotes the rupture of tumor cell plasma membranes. Specifically, this invention utilizes a glioblastoma-specific Nestin enhancer or a tumor cell-specific Survivin promoter to drive the specific expression of the NINJ1 or DTA gene, thereby enhancing the lytic and killing ability of cells. The oncolytic virus G005 expressing NINJ1 exhibits strong killing ability against tumor cells, and the tumor completely disappears in an orthotopic glioma animal model. It can also rapidly restore the weight loss in mice caused by tumor burden, demonstrating that the oncolytic virus G005 has excellent therapeutic effects against GBM.

The invention provides application of beta-1, 3 / alpha-1, 3-glucan in preparation of liver cancer postoperative recovery products, and belongs to the field of medicines. The food-grade beta-1, 3 / alpha-1, 3-glucan provided by the invention is proved to be capable of remarkably reducing the tumor load after the liver cancer operation and improving the clinical remission rate, and has important clinical significance and application value. The invention provides a new strategy for postoperative recovery of liver cancer, which is high in safety and good in tolerance, and provides a new technical scheme for reducing the risk of tumor recurrence and improving postoperative patients.

This invention relates to the field of artificial intelligence in oncology medicine, specifically disclosing a system for quantifying residual tumor burden in gastric cancer, comprising: a data acquisition and interaction terminal, an AI core computing center, and a clinical precision decision support platform; the data acquisition and interaction terminal is configured to acquire in parallel high-resolution digital pathological slides of patients after surgery, continuous physiological time-series characteristic sequences after surgery, and the molecular expression abundance of POU4F1 transcription factor and TGF-β signaling pathway in tumor tissue; the AI ​​core computing center includes a three-dimensional quantification unit for pathological images, a dynamic correction unit for physiological homeostasis, and a molecular phenotypic decision unit; the three-dimensional quantification unit for pathological images is used to automatically segment and obtain the geometric mean diameter of the primary tumor bed, the proportion of residual tumor in the primary lesion, the number of positive lymph nodes, and the proportion of residual tumor in the worst-regressed lymph nodes; the technical solution of this invention can solve the problems of coarse quantification and large subjective bias.

The invention provides a novel tumor immune typing model based on a tumor immune microenvironment and a tumor mutation load and a construction method of the novel tumor immune typing model, and belongs to the technical field of biology. According to the method, seven gene markers are obtained through screening on the basis of IMvior210 and RNA-seq data and IHC verification data of an internal immunotherapy queue, a tumor immunophenotype prediction model ImPred is designed by applying Lasso-logistic regression, and the model provides a more accurate prediction mode for classification of tumor immunophenotypes. A brand-new tumor immune typing model is provided by combining the ImmPred and the tumor TMB load level, the tumor immune typing model can remarkably improve the efficacy of tumor immune checkpoint blocking therapy effect prediction, more accurate guidance is provided for the treatment strategy of tumor patients, and the tumor immune checkpoint blocking therapy effect prediction efficiency is improved. Clinicians are better helped to provide individualized immunotherapy for patients according to the invention.

The invention belongs to the technical field of tumor immunotherapy, and relates to a method for enhancing killing of B cell lymphoma by CD19 CAR-T through an ITK inhibitor Soquelitzinib. The background is as follows: the existing CAR-T cell faces the problems of insufficient in-vivo amplification, poor persistence, T cell depletion and the like when being used for treating B cell lymphoma, and the curative effect is influenced. According to the content of the invention, it is found for the first time that Soquitzinib inhibits a CAR-T depletion process by regulating an ITK / PLC gamma signal channel. The CAR-T cell pretreated by the Soquitinib is transfused back into the body of a B-cell lymphoma tumor-bearing mouse, and the Soquitinib is continuously administered by oral administration, so that the tumor load can be relieved and the lifetime of the mouse can be prolonged by combining the Soquitinib and the CAR-T. An in-vitro experiment shows that the Soquitinib can be used for improving the killing effect of the CAR-T on tumor cells. The technical effects are as follows: the epigenetic status of CAR-T is regulated and controlled through the targeted ITK / PLC gamma pathway, and (1) the survival and killing capabilities of CAR-T cells in a tumor microenvironment are enhanced; (2) the treatment effect bottleneck caused by CAR-T cell depletion is broken through; and (3) a new safe and efficient combined treatment strategy is provided for patients with B-cell lymphoma.

The application discloses a probe set for evaluating systemic tumor burden of pancreatic cancer and application thereof, wherein the probe set comprises probes for detecting gene markers, the gene markers comprising KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, covering high-frequency and drug-related sites of pancreatic cancer, and the systemic tumor burden of a pancreatic cancer patient is monitored in real time and dynamically by performing targeted capture on plasma ctDNA alone or in combination with a personalized probe set.

The invention discloses a probe set for evaluating whole-body tumor load of small cell lung cancer and application of the probe set, the probe set comprises a plurality of oligonucleotide probes for specifically capturing mutation regions of SCLC related genes in a targeted mode, and the genes are selected from TP53, RB1, CREBBP, EGFR, PTEN, PIK3CA, LRP1B and NOTCH1; and the probe set is capable of covering at least 94.9% of at least one mutation existing in an SCLC patient sample. The invention relates to the technical field of biotechnology and molecular diagnosis, and has the beneficial effects that based on a clinical queue, the probe group incorporates high-frequency mutant genes of SCLC, can be superposed with personalized probes for use, and is used for ctDNA detection of SCLC patients and evaluation of whole-body tumor load. The SCLC cancer species specific probe group provided by the invention plays a role in monitoring tumor evolution and new mutation, can overcome the space-time heterogeneity of tumors to a certain extent, and also can improve the capture efficiency at the same time.

The application relates to the field of biological medicine, and particularly relates to application of an EGFR inhibitor in preparation of a medicine for reversing acute myeloid leukemia venetoclax drug resistance. Experimental results show that combination of osimertinib and venetoclax can significantly reduce tumor load of a venetoclax drug resistance model mouse, and obviously prolong survival time. It is shown that the combination can effectively reverse the venetoclax drug resistance, and provides a new way for the acute myeloid leukemia venetoclax drug resistance.

Methods and compositions for treating a subject suffering from adrenocortical carcinoma and having excess cortisol are disclosed. The methods provide therapeutic benefits including reduction of ACC tumor load, restoration of T-cell and natural killer (NK) cell signaling pathways, increase in T-cell and NK cell infiltration into the ACC tumor, reduction of neutrophil infiltration into the ACC tumor in the patient, and other therapeutic benefits. The methods include administration of a glucocorticoid receptor modulator (GRM) (which may be a selective glucocorticoid receptor modulator (SGRM)) and an antibody checkpoint inhibitor. In embodiments, the GRM (e.g., a SGRM) is orally administered. The GRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

The application discloses siRNA for inhibiting expression of a CREPT gene, wherein a positive sense chain nucleotide sequence of the siRNA is shown in any one of SEQ ID No. 1-3. The siRNA can inhibit the CREPT. Some siRNAs can inhibit growth of mouse colon cancer cells and growth of NIH3T3 fibrosarcoma cells. The liposome delivery drug of the si-CREPT through a delivery system can treat mouse liver cancer, and significantly reduce tumor load of the mouse liver cancer.